NovoSeven 5 mg (250 KIU) powder and solvent for solution for injection

DRUG3 trials

Sponsors

F. Hoffmann-La Roche AG, HZRM Haemophilie-Zentrum Rhein Main GmbH, Emory University, University Of Cincinnati College Of Medicine

Conditions

Acute haemorrhagic strokeHaemophilia AType 3 Von Willebrand Disease

Phase 3

rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial

RecruitingCTIS2024-517383-28-00

University Of Cincinnati College Of MedicineAcute haemorrhagic stroke

Start: 2025-07-21Target: 125Updated: 2026-01-07

A Phase III, Multicenter, Open-Label Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Prophylaxis in Patients with Type 3 Von Willebrand Disease

RecruitingCTIS2024-515622-80-00

F. Hoffmann-La Roche AGType 3 Von Willebrand Disease

Start: 2025-06-04Target: 47Updated: 2025-06-27

Phase 4

MOdern Treatment of Inhibitor-PositiVe PATiEnts with Haemophilia A – An International Low-Interventional Pragmatic Investigator Initiated Trial

RecruitingCTIS2024-516741-39-00

HZRM Haemophilie-Zentrum Rhein Main GmbH, Emory UniversityHaemophilia A

Start: 2020-01-14Target: 22Updated: 2025-10-28